ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Loss of E3 Ubiquitin Ligase RINES via CpG Methylation Relieves Suppression of STAT3 and MYC, Facilitating Multiple Tumorigeneses.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Dysregulated protein modifications alter the stability and activation status of key regulatory proteins and contribute to tumorigenesis. RING finger (RNF) proteins as E3 ubiquitin ligases, play fundamental roles in diverse biological processes, including cancer cell stemness. Through cancer epigenomic profiling, we identify tumor-specific promoter CpG methylation of the E3 ligase RINES across multiple common cancer types (esophageal, nasopharyngeal, colorectal, breast, lung, kidney, cervical, and liver), in addition to previously reported gastric cancer, which correlates with poor patient survival. We further find that RINES inhibits tumor cell growth in vivo and in vitro. Mechanistically, RINES physically interacts with STAT3 and MYC to promote their protein degradation via its E3 ubiquitin ligase activity. RING domain-dependent ubiquitin-proteasome degradation of STAT3 and MYC is essential for RINES-mediated suppression of cancer stemness. Consistently, RINES knockdown diminishes the ubiquitination of STAT3 and MYC and elevates their protein stability, which enhances cancer stem cell properties and promotes tumorigenesis. Thus, our study establishes RINES as a bona fide tumor suppressor that directly modulates STAT3 and MYC stability to restrict cancer cell stemness. RINES promoter methylation may serve as a promising epigenetic biomarker for multiple common cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.